Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2023 | $14.00 | Neutral → Underweight | JP Morgan |
| 8/8/2023 | $49.00 → $18.00 | Buy → Hold | Jefferies |
| 12/9/2022 | $56.00 | Buy | H.C. Wainwright |
| 7/6/2022 | $62.00 | In-line → Outperform | Evercore ISI |
| 6/1/2022 | $39.00 | Underperform → In-line | Evercore ISI |
| 2/9/2022 | $80.00 → $68.00 | Market Perform | SVB Leerink |
| 1/13/2022 | $85.00 → $80.00 | Market Perform | SVB Leerink |
| 11/24/2021 | $55.00 → $73.00 | Perform | Oppenheimer |
JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00
Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously
H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00